In the U.S. Andives FDA Approval for Endeavor zotarolimus – eluting coronary stent systemmark an important development in the field of interventional cardiology, Medtronic announced today that it has received approval from the U.S. Food Received and Drug Administration . For Endeavor zotarolimus – eluting coronary stent system in the treatment of coronary heart disease, which affects an estimated 13 million people in the U.S. And is the country’s cause of death can be used.

– Compared to a bare-metal stent in the ENDEAVOR II trial, the Endeavor stent has been shown to reduce the need for repeat procedures by more than 61 % at nine months. This effect is the treatment maintained, with only 7.3 % of Endeavor patients in this randomized controlled study, the a repeat procedure to three years follow – up.‘By courtesy of you can total Kaiser Daily Health Policy is see Reports, Search Within These archives, or sign up for email infeed on Imperial Daily Health policy coverage strongly supports royal network. A free service from of The Henry J. Publish. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Other articles from category "mental":

Random articles